Free radical metabolism of raloxifene in human liver microsomes

References

• Baer BR, Wienkers LC, Rock DA. (2007). Time-dependent inactivation of P450 3A4 by raloxifene: identification of Cys239 as the site of apoprotein alkylation. Chem Res Toxicol 20:954–964.
   PubMed Web of Science ®Google Scholar
• Chang JH, Kochansky CJ, Shou M. (2006). The role of P-glycoprotein in the bioactivation of raloxifene. Drug Metab Dispos 34:2073–2078.
   PubMed Web of Science ®Google Scholar
• Chen Q, Ngui JS, Doss GA, Wang RW, Cai X, DiNinno FP, Blizzard TA, Hammond ML, Stearns RA, Evans DC, Baillie TA, Tang W. (2002). Cytochrome P450 3A4-mediated bioactivation of raloxifene: irreversible enzyme inhibition and thiol adduct formation. Chem Res Toxicol 15:907–914.
   PubMed Web of Science ®Google Scholar
• Dalvie D, Smith E, Deese A, Bowlin S. (2006). In vitro metabolic activation of thiabendazole via 5-hydroxythiabendazole: identification of a glutathione conjugate of 5-hydroxythiabendazole. Drug Metab Dispos 34:709–717.
   PubMed Web of Science ®Google Scholar
• Dalvie D, Kang P, Zientek M, Xiang C, Zhou S, Obach RS. (2008). Effect of intestinal glucuronidation in limiting hepatic exposure and bioactivation of raloxifene in humans and rats. Chem Res Toxicol 21:2260–2271.
   PubMed Web of Science ®Google Scholar
• Davis JA, Greene RJ, Han S, Rock DA, Wienkers LC. (2011). Formation of raloxifene homo-dimer in CYP3A4, evidence for multi-substrate binding in a single catalytically competent P450 active site. Arch Biochem Biophys 513:110–118.
   PubMed Web of Science ®Google Scholar
• Emoto C, Nishida H, Hirai H, Iwasaki K. (2007). CYP3A4 and CYP3A5 catalyse the conversion of the N-methyl-D-aspartate (NMDA) antagonist CJ-036878 to two novel dimers. Xenobiotica 37:1408–1420.
   PubMedGoogle Scholar
• Felson DT, Zhang Y, Hannan MT, Kiel DP, Wilson PW, Anderson JJ. (1993). The effect of postmenopausal estrogen therapy on bone density in elderly women. N Engl J Med 329:1141–1146.
   PubMed Web of Science ®Google Scholar
• Hochner-Celnikier D. (1999). Pharmacokinetics of raloxifene and its clinical application. Eur J Obstet Gynecol Reprod Biol 85:23–29.
   PubMed Web of Science ®Google Scholar
• Jordan VC. (2003a). Antiestrogens and selective estrogen receptor modulators as multifunctional medicines. 1. Receptor interactions. J Med Chem 46:883–908.
   PubMed Web of Science ®Google Scholar
• Jordan VC. (2003b). Antiestrogens and selective estrogen receptor modulators as multifunctional medicines. 2. Clinical considerations and new agents. J Med Chem 46:1081–1111.
   PubMed Web of Science ®Google Scholar
• Kelminski A. (2002). The Study of Tamoxifen and Raloxifene (STAR trial) for the prevention of breast cancer. Hawaii Med J 61:209–210.
   PubMedGoogle Scholar
• Kemp DC, Fan PW, Stevens JC. (2002). Characterization of raloxifene glucuronidation in vitro: contribution of intestinal metabolism to presystemic clearance. Drug Metab Dispos 30:694–700.
   PubMed Web of Science ®Google Scholar
• Knadler MP, Lantz RJ, Gillespie TA, Allerheiligen SR, Henry DP. (1995). The disposition and metabolism of [14C]-raloxifene in humans. Pharm Res 12:S-372.
   Google Scholar
• Lim CK, Yuan ZX, Jones RM, White IN, Smith LL. (1997). Identification and mechanism of formation of potentially genotoxic metabolites of tamoxifen: study by LC-MS/MS. J Pharm Biomed Anal 15:1335–1342.
   PubMedGoogle Scholar
• Lim H-K, Yang K, Silva J. (2010). Investigation of free radical metabolism of raloxifene by NADPH-fortified human liver microsomes using liquid chromatography/LTQ-Orbitrap. In: Proceedings of the 58th ASMS Conference on Mass Spectrometry and Allied Topics, WP459, Salt Lake City, Utah, May 23–27.
   Google Scholar
• Liu H, Qin Z, Thatcher GR, Bolton JL. (2007). Uterine peroxidase-catalyzed formation of diquinone methides from the selective estrogen receptor modulators raloxifene and desmethylated arzoxifene. Chem Res Toxicol 20:1676–1684.
   PubMedGoogle Scholar
• Moore CD, Reilly CA, Yost GS. (2010). CYP3A4-Mediated oxygenation versus dehydrogenation of raloxifene. Biochemistry 49:4466–4475.
   PubMedGoogle Scholar
• Morello KC, Wurz GT, DeGregorio MW. (2003). Pharmacokinetics of selective estrogen receptor modulators. Clin Pharmacokinet 42:361–372.
   PubMed Web of Science ®Google Scholar
• Pearson JT, Wahlstrom JL, Dickmann LJ, Kumar S, Halpert JR, Wienkers LC, Foti RS, Rock DA. (2007). Differential time-dependent inactivation of P450 3A4 and P450 3A5 by raloxifene: a key role for C239 in quenching reactive intermediates. Chem Res Toxicol 20:1778–1786.
   PubMed Web of Science ®Google Scholar
• Ring BJ, Patterson BE, Mitchell MI, Vandenbranden M, Gillespie J, Bedding AW, Jewell H, Payne CD, Forgue ST, Eckstein J, Wrighton SA, Phillips DL. (2005). Effect of tadalafil on cytochrome P450 3A4-mediated clearance: studies in vitro and in vivo. Clin Pharmacol Ther 77:63–75.
   PubMed Web of Science ®Google Scholar
• Thompson DC, Cha YN, Trush MA. (1989). The peroxidase-dependent activation of butylated hydroxyanisole and butylated hydroxytoluene (BHT) to reactive intermediates. Formation of BHT-quinone methide via a chemical-chemical interaction. J Biol Chem 264:3957–3965.
   PubMed Web of Science ®Google Scholar
• Yu L, Liu H, Li W, Zhang F, Luckie C, van Breemen RB, Thatcher GR, Bolton JL. (2004). Oxidation of raloxifene to quinoids: potential toxic pathways via a diquinone methide and o-quinones. Chem Res Toxicol 17:879–888.
   PubMed Web of Science ®Google Scholar
• Yukinaga H, Takami T, Shioyama SH, Tozuka Z, Masumoto H, Okazaki O, Sudo K. (2007). Identification of cytochrome P450 3A4 modification site with reactive metabolite using linear ion trap-Fourier transform mass spectrometry. Chem Res Toxicol 20:1373–1378.
   PubMed Web of Science ®Google Scholar
• Zoia L, Argyropoulos DS. (2009). Phenoxy radical detection using 31P NMR spin trapping. J Phys Org Chem 22:1070–1077.
   Google Scholar
• Zoia L, Argyropoulos DS. (2010). Detection of ketyl radicals using 31P NMR spin trapping. J Phys Org Chem 23:505–512.
   Google Scholar